Richard L. Coats "Dick" February 14, 1936 - December 14,
Apr. 19—Richard L. Coats "Dick" February 14, 1936 — December 14, 2024. Richard L. Coats "Dick" was born February 14, 1936 in Madill, Oklahoma. Dick attended high school in Durant, Oklahoma and Suitland, Maryland. Dick attended the University of Oklahoma on a Naval scholarship. Upon graduating, Dick was accepted to the Naval Nuclear Power Program at Mare Island in Vallejo, California by Admiral Hyman Rickover. Upon completing his PhD., Dick was hired at Sandia National Laboratories in 1966, where he eventually became a division supervisor. While at Sandia, Dick was involved in several nuclear research programs which included the development of new nuclear test reactors, conducting nuclear safety studies on both current power reactor designs, and also proposed new types of power reactors for the Nuclear Regulatory Commission (NRC). During his career at Sandia, Dick was awarded the title of Distinguished Member of Technical Staff (DMTS). Dick was also the program manager for the Moly-99 medical isotope program, which resulted in a start up company in the private sector with several of his esteemed co-workers from Sandia. In addition to being a brilliant nuclear physicists and engineer, Dick was a talented artist and hobby gardener. Dick will be greatly missed by his family and his former co-workers from Sandia. Dick is survived by his loving wife of 67 years Gloria and by his four children: Cindy (husband Barry), Rick, Robin, Beth and his two devoted Bichon Frises. Per Dick's request, there will be no services.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 days ago
- Medscape
Perspective Shifts on the Use of MS Meds During Pregnancy
PHOENIX — Two new datasets support the use of potent disease-modifying therapies (DMTs) during pregnancy in women with active multiple sclerosis (MS), reinforcing a growing shift toward treatment when the potential benefit to the mother outweighs the risks. Both studies — one involving the anti-CD20 monoclonal antibody ofatumumab and the other the integrin receptor antagonist natalizumab — are observational, but they provide a foundation for taking a proactive rather than reactive approach to treating pregnant women with active MS, said Riley M. Bove, MD, associate professor of neurology, University of California San Francisco. Bove emphasized that a 'we-don't-know' approach is no longer acceptable when counseling pregnant women with active disease. As first author of the ofatumumab study — presented on May 29 at Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting— she followed up with a lecture the next day, explaining that evidence is now available to guide treatment decisions. Relevant Data While significant knowledge gaps remain about the relative risks of DMTs to fetal development and pregnancy outcomes, it is well established that women with active disease 'will be harmed if we do not help,' Bove said. She and others now believe that the available data, even if observational, are relevant and useful in guiding decisions that affect both maternal and fetal health. The new data on ofatumumab and natalizumab offer a clear example. In an ongoing registry, ofatumumab exposure has been documented in 669 pregnancies. Of these, 221 were reported prior to 2023, allowing for assessment of both short- and long-term outcomes. In most cases (87%), exposure occurred during the first trimester. Adverse outcomes were reported, including spontaneous abortions in 12.6% of cases, preterm births in 9.6%, and minor congenital malformations in two infants (< 1%). However, these rates are 'in line with the background rates observed in the general population,' Bove noted. She emphasized that such data are important when weighing treatment decisions against the known risks of active disease, which can lead to irreversible brain injury in the mother. The natalizumab data, presented as a late-breaking abstract at CMSC on May 30, reflected 16 years of experience at a single center. Tracking began in 2008, when two pregnancies were identified in women already receiving natalizumab. Through 2024, no increased risk for adverse pregnancy outcomes was observed, while natalizumab treatment was associated with meaningful improvements in MS disease control. A total of 58 pregnancies in 43 women have been tracked at the Rocky Mountain MS Clinic in Salt Lake City, according to Katrina Bawden, FNP-C, a nurse practitioner who has been involved since the registry began. Reevaluating Natalizumab She noted that outcomes were analyzed in women who discontinued natalizumab after learning they were pregnant as well as those who continued treatment into the third trimester. Among the 38 pregnancies in which natalizumab was stopped, 13 women experienced clinical relapses, and four others showed new lesions on MRI. In contrast, among the 20 pregnancies where treatment was continued, there were no relapses and no MRI evidence of disease activity. Pregnancy complications were observed, including one fetal malformation and 10 miscarriages, but Bawden noted that these figures — like those in the ofatumumab registry — are consistent with background rates. 'Of the three fetal deaths, all occurred in those who discontinued natalizumab,' she said. She noted that all 10 of the women who miscarried had healthy term full term deliveries in a subsequent pregnancy while remaining on natalizumab. Compared to the start of the tracking period, Bawden said the data have prompted clinicians at her clinic to reevaluate the benefit-risk balance of using natalizumab during pregnancy. 'Women at the Rocky Mountain MS Clinic who become pregnant while treated with natalizumab, using shared decision-making, are now given the option of continuing natalizumab every 8 weeks throughout pregnancy with the last dose scheduled at 34 weeks' gestation,' Bawden said. 'Illogical Guidance' Caring for pregnant women with MS is a complex challenge, given the incomplete information available. However, Bove — co-author of a 2024 paper on practical considerations for weighing the risks and benefits of DMT use during pregnancy — said that strictly following drug labeling is not helpful in guiding clinical decisions. She noted that current recommendations are inconsistent across drug classes, vary between the FDA and the European Medicines Agency, and often fail to reflect the latest science — resulting in guidance that is ultimately 'illogical.' Moreover, labeling continues to evolve, and pregnancy-related use of DMTs remains a dynamic area, with new data — such as the recent studies presented at CMSC — shaping clinical strategies. Bove emphasized that it is the clinician's responsibility to stay informed as the evidence develops, in order to support shared decision-making. This includes staying up to date on when to treat active disease during pregnancy, when to restart therapy if it was paused, and how to weigh the benefit-risk profile of DMTs for women who choose to breastfeed. When making MS treatment decisions during pregnancy, the adage 'first, do no harm' has traditionally focused on fetal risk. But Bove pointed out that withholding treatment may, in many cases, pose greater harm to the mother, underscoring the need for a balanced discussion that considers risks to both mother and fetus.
Medscape
3 days ago
- Medscape
Evidence Shifts Perspective on MS Drug Use in Pregnancy
PHOENIX — Two new datasets support the use of potent disease-modifying therapies (DMTs) during pregnancy in women with active multiple sclerosis (MS), reinforcing a growing shift toward treatment when the potential benefit to the mother outweighs the risks. Both studies — one involving the anti-CD20 monoclonal antibody ofatumumab and the other the integrin receptor antagonist natalizumab — are observational, but they provide a foundation for taking a proactive rather than reactive approach to treating pregnant women with active MS, said Riley M. Bove, MD, associate professor of neurology, University of California San Francisco. Bove emphasized that a 'we-don't-know' approach is no longer acceptable when counseling pregnant women with active disease. As first author of the ofatumumab study — presented on May 29 at Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting— she followed up with a lecture the next day, explaining that evidence is now available to guide treatment decisions. Relevant Data While significant knowledge gaps remain about the relative risks of DMTs to fetal development and pregnancy outcomes, it is well established that women with active disease 'will be harmed if we do not help,' Bove said. She and others now believe that the available data, even if observational, are relevant and useful in guiding decisions that affect both maternal and fetal health. The new data on ofatumumab and natalizumab offer a clear example. In an ongoing registry, ofatumumab exposure has been documented in 669 pregnancies. Of these, 221 were reported prior to 2023, allowing for assessment of both short- and long-term outcomes. In most cases (87%), exposure occurred during the first trimester. Adverse outcomes were reported, including spontaneous abortions in 12.6% of cases, preterm births in 9.6%, and minor congenital malformations in two infants (< 1%). However, these rates are 'in line with the background rates observed in the general population,' Bove noted. She emphasized that such data are important when weighing treatment decisions against the known risks of active disease, which can lead to irreversible brain injury in the mother. The natalizumab data, presented as a late-breaking abstract at CMSC on May 30, reflected 16 years of experience at a single center. Tracking began in 2008, when two pregnancies were identified in women already receiving natalizumab. Through 2024, no increased risk for adverse pregnancy outcomes was observed, while natalizumab treatment was associated with meaningful improvements in MS disease control. A total of 58 pregnancies in 43 women have been tracked at the Rocky Mountain MS Clinic in Salt Lake City, according to Katrina Bawden, FNP-C, a nurse practitioner who has been involved since the registry began. Reevaluating Natalizumab She noted that outcomes were analyzed in women who discontinued natalizumab after learning they were pregnant as well as those who continued treatment into the third trimester. Among the 38 pregnancies in which natalizumab was stopped, 13 women experienced clinical relapses, and four others showed new lesions on MRI. In contrast, among the 20 pregnancies where treatment was continued, there were no relapses and no MRI evidence of disease activity. Pregnancy complications were observed, including one fetal malformation and 10 miscarriages, but Bawden noted that these figures — like those in the ofatumumab registry — are consistent with background rates. 'Of the three fetal deaths, all occurred in those who discontinued natalizumab,' she said. She noted that all 10 of the women who miscarried had healthy term full term deliveries in a subsequent pregnancy while remaining on natalizumab. Compared to the start of the tracking period, Bawden said the data have prompted clinicians at her clinic to reevaluate the benefit-risk balance of using natalizumab during pregnancy. 'Women at the Rocky Mountain MS Clinic who become pregnant while treated with natalizumab, using shared decision-making, are now given the option of continuing natalizumab every 8 weeks throughout pregnancy with the last dose scheduled at 34 weeks' gestation,' Bawden said. 'Illogical Guidance' Caring for pregnant women with MS is a complex challenge, given the incomplete information available. However, Bove — co-author of a 2024 paper on practical considerations for weighing the risks and benefits of DMT use during pregnancy — said that strictly following drug labeling is not helpful in guiding clinical decisions. She noted that current recommendations are inconsistent across drug classes, vary between the FDA and the European Medicines Agency, and often fail to reflect the latest science — resulting in guidance that is ultimately 'illogical.' Moreover, labeling continues to evolve, and pregnancy-related use of DMTs remains a dynamic area, with new data — such as the recent studies presented at CMSC — shaping clinical strategies. Bove emphasized that it is the clinician's responsibility to stay informed as the evidence develops, in order to support shared decision-making. This includes staying up to date on when to treat active disease during pregnancy, when to restart therapy if it was paused, and how to weigh the benefit-risk profile of DMTs for women who choose to breastfeed. When making MS treatment decisions during pregnancy, the adage 'first, do no harm' has traditionally focused on fetal risk. But Bove pointed out that withholding treatment may, in many cases, pose greater harm to the mother, underscoring the need for a balanced discussion that considers risks to both mother and fetus.
Yahoo
30-05-2025
- Yahoo
The Inner Circle acknowledges, John Amos Brusven as a Pinnacle Professional Member
HENDERSON, Nev. , May 30, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, John Amos Brusven is acknowledged as a Pinnacle Professional Member Inner Circle of Excellence for his contributions to Upholding Excellence in Toxicology and Biopharmaceutical Quality Standards. John Amos Brusven has established a strong reputation in the fields of toxicology and biopharmaceuticals, bringing over 15 years of experience to his current role as Director of Quality at Donor Services Laboratory. In this position, Mr. Brusven plays a critical role in ensuring compliance with rigorous quality standards and supporting operational efficiency across laboratory processes. His responsibilities include overseeing the timely fulfillment of client orders, verifying that donor organs meet safety requirements for infectious disease screening, and confirming the accuracy of all demographic data related to tissue acquisitions. Additionally, he manages client communications via the organization's quality email line, ensuring transparency and prompt resolution of inquiries, including the coordination of delay notifications when necessary. Mr. Brusven earned a Bachelor of Science in microbiology with a minor in chemistry from Northern Arizona University in 2015. He has further distinguished himself through certifications with the College of American Pathologists as a CAP Inspection Team member and by completing HAZWOPER OSHA Training, enhancing his qualifications in lab safety and regulatory compliance. Active in the professional community, he is affiliated with the ASACP Association and remains committed to civic engagement as a regular donor to charitable organizations. With a decade of industry experience behind him, Mr. Brusven continues to prioritize quality, safety, and service. Looking ahead, he aims to further expand his impact in the field of biopharmaceuticals through continued innovation and leadership. Contact: Katherine Green, 516-825-5634, editorialteam@ View original content: SOURCE The Inner Circle Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
